R&D | February 24, 2026
Boehringer Ingelheim India and NIPER Raebareli join forces to boost pharma innovation
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
Experts caution that realizing AI’s potential requires careful management and risk mitigation
India’s pharmaceutical sector stands at a pivotal inflection point
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The primary goal of the collaboration is joint research into trending and next-generation molecules
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
